Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

Alan Cooper, Sravya Tumuluru, Kyle Kissick, Girish Venkataraman, Joo Y Song, Andrew Lytle, Gerben Duns, Jovian Yu, Nikita Kotlov, Alexander Bagaev, Brendan Paul Hodkinson, Srimathi Srinivasan, Sonali M. Smith, David W. Scott, Christian Steidl, James Godfrey, Justin Kline

Blood (2023) 142 (Supplement 1): 851.

https://doi.org/10.1182/blood-2023-182390

Published: 2023

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith

Blood (2022) 140 (Supplement 1): 6594–6595.

https://doi.org/10.1182/blood-2022-168444

Published: 2022

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Sravya Tumuluru, James Godfrey, Jovian Yu, Alan Cooper, Xiufen Chen, Gerben Duns, Sonali M. Smith, Christian Steidl, Justin Kline

Blood (2021) 138 (Supplement 1): 449.

https://doi.org/10.1182/blood-2021-153724

Published: 2021

Journal Articles

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline

Blood (2021) 137 (24): 3454–3459.

https://doi.org/10.1182/blood.2020009148

Published: 2021

Journal Articles

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD, Wenjun Kang, MS, Lei Huang, PhD, Silvia Coma, PhD, Roy Maute, PhD, Mark P. Chao, MD PhD, Jonathan A Pachter, PhD, Sonali Smith, MD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143304

Published: 2020

Journal Articles

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

Jovian Yu, MD, Xiufen Chen, PhD, James Godfrey, MD, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Mengjie Chen, PhD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-137171

Published: 2020

Journal Articles

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Justin Kline, James Godfrey, Stephen M. Ansell

Blood (2020) 135 (8): 523–533.

https://doi.org/10.1182/blood.2019000847

Published: 2020

Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 924.

https://doi.org/10.1182/blood-2019-131562

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W. MacNabb, Robert Orlowski, Sonali M. Smith, Justin Kline

Blood (2019) 133 (21): 2279–2290.

https://doi.org/10.1182/blood-2018-10-879015

Published: 2019

Includes: Supplemental data

Journal Articles

PD-L1 Gene Alterations Identify a Unique Subset of Diffuse Large B Cell Lymphoma That Harbors a T Cell Inflamed Phenotype

Justin Kline, MD, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Robert J Orlowski, MD, Sonali M. Smith, MD, Riyue Bao, PhD

Blood (2018) 132 (Supplement 1): 673.

https://doi.org/10.1182/blood-2018-99-117189

Published: 2018

Journal Articles

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Justin Kline, MD, Hongtao Liu, MD PhD, Tallarico Michael, MD, Andrew S Artz, MD, James Godfrey, MD, Emily K Curran, MD, Wendy Stock, MD, Sonali M. Smith, MD, Michael R. Bishop, MD

Blood (2018) 132 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2018-99-115108

Published: 2018

NARROW

A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

PD-L1 Gene Alterations Identify a Unique Subset of Diffuse Large B Cell Lymphoma That Harbors a T Cell Inflamed Phenotype

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only